Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Arzerra® (ofatumumab) – Expanded indication
August 31, 2016 – Genmab announced the FDA approval of Arzerra (ofatumumab) in combination with fludarabine and cyclophosphamide (FC) for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL).
